UNSPSC 51142424: Dihydroergotamine mesilate or mesylate

This classification denotes a nonnarcotic analgesic and dopamine agonist with the molecular formula C33H37N5O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81AXN7R2QT, chemically known as ergotoman-3',6',18-trione,9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'.alpha.)-, monomethanesulfonate (salt), but more generally known as dihydroergotamine mesylate, which bears US NIH Compound Identifier 3066.

UNSPSC 51142424 Dihydroergotamine mesilate or mesylate is a Commodity code that covers specific pharmaceutical products, but recent state and local solicitations tagged with this code diverge significantly from its nominal scope. The three recent opportunities posted under or aligned with this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply agreements—none of which address dihydroergotamine specifically. State and local governments procuring under this code are purchasing broader pharmaceutical supply solutions, including emergency medications, OTC products, and manufacturer-direct prescription fulfillment programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which spans state and local entities across participating states including Oregon).

Recent activity is concentrated in Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative vehicle extending reach across participating jurisdictions. Representative opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) gathering vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing contracts for generic pharmaceuticals and OTC products across authorized wholesalers with a July 1, 2026 effective date. The code's recent activity reflects state and local demand for pharmaceutical supply chain solutions rather than a single active drug product, and the mismatch between the nominal commodity (dihydroergotamine) and actual solicitations suggests limited direct relevance to firms targeting this specific pharmaceutical.